Advertisement

Topics

Sirna Therapeutics, Inc. Company Profile

13:40 EST 16th December 2018 | BioPortfolio

The scientific community considers RNA RNARibonucleic acid. A long chain polymer of genetic material similar to DNA except that it is usually found in a single-stranded form rather than as a double helix, it is made up of the ribo nucleotides A, G, C, and U (instead of T), it is somewhat less resistant to cellular degradation enzymes than DNA, and it functions most often as a transient messenger of genetic information rather than as a permanent store-house as is the case for DNA.interference (RNAi)RNAiRNA interference. A natural cellular mechanism by which RNA is recognized as “foreign” due to its existence in a double-stranded form. This results in the degradation of the double-stranded RNA, along with single-stranded RNA having the same sequence. the breakthrough biological discovery of the decade with the potential to change how diseases are treated. Sirna Therapeutics, Inc. is leading the industry in developing a new class of drugs based on RNAi—drugs that we believe will significantly improve human health.With our unmatched chemistry and biology expertise, seasoned leadership and broad therapeutic pipeline, Sirna is demonstrating that short interfering RNA (siRNA)siRNA short interfering RNA. An intermediate in the RNAi process in which the long double-stranded RNA has been cut up into short (~21 nucleotides) double-stranded RNA. The siRNA stimulates the cellular machinery to cut up other single-stranded RNA having the same sequence as the siRNA. can be chemically optimized and efficiently delivered to create therapeutically relevant compounds with drug-like properties and clinical effect

Location

185 Berry Street, Suite 6504
San Francisco
California
94107
United States of America

Contact

Phone: (415) 512-7200
Fax: (415) 512-7022
Email: info@sirna.com


News Articles [699 Associated News Articles listed on BioPortfolio]

FDA approves Alnylam’s siRNA drug Onpattro for rare disorder

The drug is the first approved treatment for the condition, as well as the first

Arabidopsis HTT2 Improves Thermotolerance in Heading Chinese Cabbage

In Arabidopsis, the HEAT-INDUCED TAS1 TARGET2 (HTT2) is an important thermotolerance gene that is silenced by ta-siR255, an siRNA. This ta-siR255 siRNA is absent from heading Chinese cabbage (Brassica...

Sirnaomics to Start US Trial of siRNA Treatment for Bile Duct Cancer

Sirnaomics of Maryland was approved to start US trials of its anti-cancer/anti-fibrosis siRNA (small interfering RNA) therapeutic in patients with advanced cholangiocarcinoma (CCA). Sirnaomics has fac...

Alnylam reports further progress on broadening the therapeutic potential of RNAi

Alnylam Pharmaceuticals, Inc., the leading RNAi therapeutics company, announced today further progress on the Company's platform efforts in extrahepatic delivery of novel siRNA conjugates, including c...

Aphios Granted United States Patent for Improved Delivery of Targeted siRNA Using Nanotechnology

WOBURN, Mass., June 05, 2018 (GLOBE NEWSWIRE) -- Aphios Corporation today announced that it has been granted United States Patent No. 9,981,238 entitled “Apparatus and Methods for Making Nanosome...

Antioxidant compound combines with a small polymer to form nanoparticles that safely deliver siRNA into cells: http://ow.ly/JeaS30lSXpG 

Antioxidant compound combines with a small polymer to form nanoparticles that safely deliver siRNA into cells: http://ow.ly/JeaS30lSXpG 

Taming preeclampsia at its source. #siRNA delivery to the placenta silences the proteins responsible for #preeclampsia https://go.nature.com/2E6A3KN  #NBTNVpic.twitter.com/jnS3Xnka4K

Taming preeclampsia at its source. #siRNA delivery to the placenta silences the proteins responsible for #preeclampsia https://go.nature.com/2E6A3KN  #NBTNV pic.twitter.com/jnS3Xnka4K

The RTI's Khvorova & Moore labs have made the Dec @NatureBiotech cover & @NatureNews!!! @AntonTuranov et al. use a baboon model of #preeclampsia to show that a protein responsible for this disorder is reduced after a single intravenous injection of #siRNA

The RTI's Khvorova & Moore labs have made the Dec @NatureBiotech cover & @NatureNews!!! @AntonTuranov et al. use a baboon model of #preeclampsia to show that a protein responsible for this...

PubMed Articles [697 Associated PubMed Articles listed on BioPortfolio]

Strategies for improving the specificity of siRNAs for enhanced therapeutic potential.

RNA interference has become a tool of choice in the development of drugs in various therapeutic areas of Post Transcriptional Gene Silencing (PTGS). The critical element in developing successful RNAi ...

Towards Understanding Liposome-Based siRNA Delivery Vectors: Atomic-Scale Insight into siRNA-Lipid Interactions.

Liposome carriers for delivering small interfering RNA (siRNA) into target cells are of tremendous importance because the siRNA-based therapy offers a completely new approach for treating a wide range...

GalNAc-siRNA Conjugates: Leading the Way for Delivery of RNAi Therapeutics.

Short-interfering RNA (siRNA)-induced RNAi responses have great potential to treat a wide variety of human diseases from cancer to pandemic viral outbreaks to Parkinson's Disease. However, before siRN...

Lipid nanoparticles with minimum burst release of TNF-α siRNA show strong activity against rheumatoid arthritis unresponive to methotrexate.

TNF-α siRNA has shown promising therapeutic benefits in animal models of rheumatoid arthritis. However, there continues to be a need for siRNA delivery systems that have high siRNA encapsulation effi...

Exploring PAZ/3'-overhang interaction to improve siRNA specificity. A combined experimental and modeling study.

The understanding of the dynamical and mechanistic aspects that lie behind siRNA-based gene regulation is a requisite to boost the performance of siRNA therapeutics. A systematic experimental and comp...

Clinical Trials [178 Associated Clinical Trials listed on BioPortfolio]

EphA2 Gene Targeting Using Neutral Liposomal Small Interfering RNA Delivery

The goal of this clinical research study is to learn about the safety of siRNA-EphA2-DOPC when given to patients with advanced, recurrent cancer. Researchers also want to learn the highes...

Safety Study of CALAA-01 to Treat Solid Tumor Cancers

Rationale: CALAA-01 is a targeted therapeutic designed to inhibit tumor growth and/or reduce tumor size. The active ingredient in CALAA-01 is a small interfering RNA (siRNA). This siRNA in...

Immunotherapy of Melanoma With Tumor Antigen RNA and Small Inhibitory RNA Transfected Autologous Dendritic Cells

Transfection with siRNA targeting the immunoproteasome alters proteasome-mediated antigen processing by the dendritic cell, generating TAA-derived peptides that we hypothesize, based on pr...

A Dose Escalation Trial of an Intravitreal Injection of Sirna-027 in Patients With Subfoveal Choroidal Neovascularization (CNV) Secondary to Age-Related Macular Degeneration (AMD)

The purpose of this study will be to assess the safety and tolerability and dose-limiting toxicity of a single intravitreal injection of Sirna-027 (AGN211745) and to assess the anatomical ...

iExosomes in Treating Participants With Metastatic Pancreas Cancer With KrasG12D Mutation

This phase I trial studies the best dose and side effects of mesenchymal stromal cells-derived exosomes with KrasG12D siRNA (iExosomes) in treating participants with pancreatic cancer with...

Companies [1309 Associated Companies listed on BioPortfolio]

Sirna Therapeutics, Inc.

The scientific community considers RNA RNARibonucleic acid. A long chain polymer of genetic material similar to DNA except that it is usually found in a single-stranded form rather than as a double he...

BioMolecular Therapeutics, Inc.

An early-stage biopharmaceutical company, BMT is pioneering the development of novel RNAi therapeutics to prevent and treat age-related macular degeneration based on the company's proprietary technolo...

Traversa Therapeutics

Traversa Therapeutics, Inc. (www.traversathera.com) is a San Diego, California-based biopharmaceutical company engaged in the discovery, development and commercialization of RNAi ...

Roche Madison Inc.

Roche Madison Inc. is a leader in the fields of RNA interference and gene therapy, based upon its expertise in non-viral nucleic acid chemistry and delivery. Effective and safe siRNA delivery represen...

Intradigm Corporation

Intradigm is developing siRNA-derived cancer therapeutics utilizing its proprietary RNAi technology. Intradigm has led the advancement of siRNA from the test tube to a potent, tissue-targeted, system...

More Information about "Sirna Therapeutics, Inc." on BioPortfolio

We have published hundreds of Sirna Therapeutics, Inc. news stories on BioPortfolio along with dozens of Sirna Therapeutics, Inc. Clinical Trials and PubMed Articles about Sirna Therapeutics, Inc. for you to read. In addition to the medical data, news and clinical trials, BioPortfolio also has a large collection of Sirna Therapeutics, Inc. Companies in our database. You can also find out about relevant Sirna Therapeutics, Inc. Drugs and Medications on this site too.

Advertisement
Quick Search
Advertisement
Advertisement

 

Relevant Topics

Bioinformatics
Bioinformatics is the application of computer software and hardware to the management of biological data to create useful information. Computers are used to gather, store, analyze and integrate biological and genetic information which can then be applied...

DNA sequencing
DNA sequencing is the process of determining the precise order of nucleotides within a DNA molecule. During DNA sequencing, the bases of a small fragment of DNA are sequentially identified from signals emitted as each fragment is re-synthesized from a ...


Corporate Database Quicklinks



Searches Linking to this Company Record